Unbound brain concentration determines receptor occupancy: A correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats

Drug Metabolism and Disposition

Volumn 37, Issue 7, 2009, Pages 1548-1556

  Liu, Xingrong ^a,b   Vilenski, Olga ^a   Kwan, Joyce ^a   Apparsundaram, Subbu ^a   Weikert, Robert ^a  

^a ROCHE BIOSCIENCE   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMFEBUTAMONE; BENZYLAMINE DERIVATIVE; CITALOPRAM; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; DULOXETINE; INDATRALINE; NOMIFENSINE; NS 2359; RADIOLIGAND; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; VANOXERINE; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN HOMOGENATE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RECEPTOR OCCUPANCY;

ANIMALS; BINDING, COMPETITIVE; BRAIN; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; PROTEIN BINDING; RADIOPHARMACEUTICALS; RATS; RATS, LONG-EVANS; SEROTONIN; STATISTICS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 67649408864     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.026674     Document Type: Article

References (33)

1. Apparsundaram S, Stockdale DJ, Henningsen RA, Milla ME, and Martin RS (2008) Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism. J Pharmacol Exp Ther 327:982-990.
2. 99mTc-TRODAT-1 SPECT study. J Affect Disord 89:115-123.
3. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, and Richelson E (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401.
4. Becker S and Liu X (2006) Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos 34:855-861.
5. Beyer CE and Cremers TI (2008) Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? Eur J Pharmacol 580:350-354.
6. Bosworth N and Towers P (1989) Scintillation proximity assay. Nature 341:167-168.
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Cox EH, Kerbusch T, Van der Graaf PH, and Danhof M (1998) Pharmacokineticpharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 284:1095-1103. (Pubitemid 28130839)
9. Fridén M, Gupta A, Antonsson M, Bredberg U, and Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719. (Pubitemid 47296068)
10. Hammarlund-Udenaes M, Fridén M, Syvänen S, and Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25:1737-1750.
11. Hammarlund-Udenaes M, Paalzow LK, and de Lange EC (1997) Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method. Pharm Res 14:128-134. (Pubitemid 27146353)
12. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338. (Pubitemid 36124162)
13. Kalvass JC, Maurer TS, and Pollack GM (2007a) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666. (Pubitemid 46513270)
14. 50, u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323:346-355.
15. Liu X and Chen C (2005) Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Devel 8:505-512. (Pubitemid 40917412)
16. Liu X, Chen C, and Smith BJ (2008) Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 325:349-356. (Pubitemid 351574780)
17. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313:1254-1262. (Pubitemid 40727030)
18. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34:1443-1447. (Pubitemid 44285383)
19. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, and Monshouwer M (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787-793.
20. Maurer TS, Debartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181. (Pubitemid 40023529)
21. Meyer JH (2008) Applying neuroimaging ligands to study major depressive disorder. Semin Nucl Med 38:287-304. (Pubitemid 351726327)
22. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, and Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835. (Pubitemid 38625335)
23. Paxinos G and Watson C (1998) The Rat Brain in Stereotaxic Coordinates, 4th ed. Academic Press, San Diego.
24. Porsolt RD, Le Pichon M, and Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732. (Pubitemid 8073804)
25. Steru L, Chermat R, Thierry B, and Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85:367-370. (Pubitemid 15123115)
26. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, et al. (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518-1535.
27. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, and Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205-213. (Pubitemid 46956363)
28. Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, and Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282-1290. (Pubitemid 43345304)
29. Syvänen S, Xie R, Sahin S, and Hammarlund-Udenaes M (2006) Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res 23:705-717.
30. Torres GE, Gainetdinov RR, and Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4:13-25. (Pubitemid 37271085)
31. van Waarde A (2000) Measuring receptor occupancy with PET. Curr Pharm Des 6:1593-1610. (Pubitemid 30765413)
32. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, and Read KD (2009) Receptor occupancy and brain free fraction. Drug Metab Dispos 37:753-760.
33. Wilkinson GR (2001) Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination, in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed (Hardman JG, Limbird LE, and Goodman Gilman A eds) pp 3-30, McGraw-Hill, New York.